194 related articles for article (PubMed ID: 33411110)
1. Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant.
Zhao T; Chen Y; Wang D; Wang L; Dong P; Zhao S; Wang C; Meng Q; Sun H; Liu K; Wu J
Cardiovasc Drugs Ther; 2022 Feb; 36(1):121-129. PubMed ID: 33411110
[TBL] [Abstract][Full Text] [Related]
2. LKY-047: First Selective Inhibitor of Cytochrome P450 2J2.
Phuc NM; Wu Z; O Y; Lee JH; Oh S; Song GY; Liu KH
Drug Metab Dispos; 2017 Jul; 45(7):765-769. PubMed ID: 28461575
[TBL] [Abstract][Full Text] [Related]
3. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
4. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Clin Pharmacol; 1999 Jun; 39(6):567-77. PubMed ID: 10354960
[TBL] [Abstract][Full Text] [Related]
5. Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban.
Tang LWT; Wu G; Chan ECY
J Pharmacol Exp Ther; 2022 Aug; 382(2):123-134. PubMed ID: 35640957
[TBL] [Abstract][Full Text] [Related]
6. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
[TBL] [Abstract][Full Text] [Related]
7. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.
Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R
J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214
[TBL] [Abstract][Full Text] [Related]
8. Identification of human cytochrome P450 isoforms involved in the metabolism of brotizolam.
Senda C; Kishimoto W; Sakai K; Nagakura A; Igarashi T
Xenobiotica; 1997 Sep; 27(9):913-22. PubMed ID: 9381732
[TBL] [Abstract][Full Text] [Related]
9. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes.
Crewe HK; Ellis SW; Lennard MS; Tucker GT
Biochem Pharmacol; 1997 Jan; 53(2):171-8. PubMed ID: 9037249
[TBL] [Abstract][Full Text] [Related]
10. Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Lee CA; Jones JP; Katayama J; Kaspera R; Jiang Y; Freiwald S; Smith E; Walker GS; Totah RA
Drug Metab Dispos; 2012 May; 40(5):943-51. PubMed ID: 22328583
[TBL] [Abstract][Full Text] [Related]
11. Involvement of multiple cytochrome P450 isoenzymes in drug interactions between ritonavir and direct oral anticoagulants.
Tamemoto Y; Shibata Y; Hashimoto N; Sato H; Hisaka A
Drug Metab Pharmacokinet; 2023 Dec; 53():100498. PubMed ID: 37778107
[TBL] [Abstract][Full Text] [Related]
12.
Zhang N; Liu J; Chen Z; Dou W
Pharm Biol; 2019 Dec; 57(1):571-576. PubMed ID: 31456483
[No Abstract] [Full Text] [Related]
13. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Cheong EJ; Goh JJ; Hong Y; Venkatesan G; Liu Y; Chiu GN; Kojodjojo P; Chan EC
Drug Metab Dispos; 2017 Mar; 45(3):260-268. PubMed ID: 28053220
[TBL] [Abstract][Full Text] [Related]
14.
Xu S; Zhang F; Chen D; Su K; Zhang L; Jiang R
Pharm Biol; 2020 Dec; 58(1):308-313. PubMed ID: 32285742
[No Abstract] [Full Text] [Related]
15. Inhibition of Cytochrome P450 2J2-Mediated Metabolism of Rivaroxaban and Arachidonic Acid by Ibrutinib and Osimertinib.
Wang Z; Yong Chan EC
Drug Metab Dispos; 2022 Oct; 50(10):1332-1341. PubMed ID: 35817438
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies.
Hamaoka N; Oda Y; Hase I; Asada A
Br J Anaesth; 2001 Apr; 86(4):540-4. PubMed ID: 11573629
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of triflumuron in the human liver: Contribution of cytochrome P450 isoforms and esterases.
Timoumi R; Buratti FM; Abid-Essefi S; Dorne JCM; Testai E
Toxicol Lett; 2019 Sep; 312():173-180. PubMed ID: 31082524
[TBL] [Abstract][Full Text] [Related]
18. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
Taguchi K; Konishi T; Nishikawa H; Kitamura S
Xenobiotica; 1999 Sep; 29(9):899-907. PubMed ID: 10548450
[TBL] [Abstract][Full Text] [Related]
19. Plant natural product plumbagin presents potent inhibitory effect on human cytochrome P450 2J2 enzyme.
Lu J; Liu D; Zhou X; Chen A; Jiang Z; Ye X; Liu M; Wang X
Phytomedicine; 2018 Jan; 39():137-145. PubMed ID: 29433675
[TBL] [Abstract][Full Text] [Related]
20. In vitro Inhibitory Effects of Cynaroside on Human Liver Cytochrome P450 Enzymes.
Wang L; Ma X; Wang J; Li C
Pharmacology; 2019; 104(5-6):296-302. PubMed ID: 31587003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
